Drug Trial Radar · NCT06117566
A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Nov 18, 2022
Primary completion
Nov 9, 2025
Study completion Nov 9, 2025
Sponsor
- Lead sponsor
- Shanghai Jiatan Pharmatech Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390 combined with Toripalimab in patients with advanced solid tumors. The main questions it aims to answer are: * the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of WX390; * safety and preliminary in combined therapy. Participants will be treated with WX390 orally and Toripalimab intravenously, and follow the efficacy and safety evaluation according to the protocol.
Conditions
- Solid Tumor
Interventions
WX390Drug
WX390 tablet, once a day
ToripalimabDrug
240 mg, Day 1, every 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) in DLT observation periodTime frame: up to 24 weeks
- Progression-free survival rate (PFS rate)Time frame: up to 24 weeks
- Objective response rate (ORR)Time frame: up to 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
the first affiliated hospital of Jilin university
Changchun, Jilin, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.